Traditionally people living with complex long-term conditions attend the hospital on a scheduled basis for a routine review, which means that care does not coincide with a flare or specific clinical need when care and clinical support are most valuable and effective. In recent years taking responsibility for our own health and well-being has become more and more important and E-Health has emerged as a great tool for patients to remain prolonged periods in remission. E-health also has great benefits for the physicians, hospital, and the society as a whole, and can drastically reduce the use of heavy medication, emergency admissions, surgeries, and other expensive treatments.
The CalproSmart Self-Test is used at home by IBD patients to monitor their inflammation status in the bowel. By following the simple step-by-step guide and capturing an image of the test cassette using a mobile phone, the results are read by an e-health application and are displayed, showing the inflammation level both quantitative (mg/kg) and with traffic light indicator for the patient. Clinicians are also directly alerted when a patient may need specific intervention or care, which means that flares can be managed quickly and effectively, often dealing with symptoms before reaching a full flare-up.
“My IBD Care” is an IBD management app developed by Ampersand that provides engaging & effective learning and communication tools, to help patients consistently and confidently manage their Crohn’s or Ulcerative Colitis. In addition to extensive self-management support, Ampersand Health’s digital therapeutic is an interface between clinicians and those living with these conditions, enabling asynchronous communication and remote monitoring.
The combination of self-monitoring IBD using the CalproSmart Self-Test and Ampersand’s “My IBD Care” app will now enable patients to get the right support when they need it most, tackling challenges as soon as they arise rather than waiting for a routine check-in. When a patient initiates a CalproSmart self-test from home, the results are shared in the ”My IBD Care” app for clinicians to review – a single dashboard portal that provides a 360 view of a person’s condition.
Based on previously self-reported data, the possibility for clinicians to be directly alerted when a patient may need specific intervention or care has led to 50% fewer A&E admissions, 47% increase in healthcare service efficiencies, and is preferred by 85% of patients compared with traditional models.
“This partnership with Calpro marks an important milestone in enabling patients to feel more in control of their condition. My IBD Care is the ideal platform for the CalproSmart self-test, meaning that patients and clinicians can monitor important biomarkers without checking multiple siloed systems to give an accurate view of a person’s symptoms and progress,” says Nader Alaghband, Founder & CEO of Ampersand Health. “As part of My IBD Care, the CalproSmart self-test frees up resources and time in hospitals for clinicians, enabling them to focus on providing care, whilst supporting those living with long term inflammatory conditions to feel empowered, involved and informed” continues Mr. Alaghband.
“Healthcare is becoming an integral part of our everyday lives – regardless of whether we are healthy or ill, young or old. E-Health has in the recent years emerged as a great tool for patients to remain prolonged periods in remission,” says Anne Thjømøe, Chief Executive Officer of Calpro AS. “This collaboration combines the strengths of our two organizations and will help deliver the future of IBD patient care to both patients and health care professionals. We fundamentally believe that this collaboration builds better, safer, more individualized care for patients”.
Ampersand Health specializes in immune-mediated disorders. Through personalized digital therapies and providing support to individuals so that they can self-manage their long-term conditions, they help improve patients’ overall wellbeing. Ampersand has seen great success with ”My IBD Care”; a disease-specific digital therapeutic app used by over 50,000 people in the UK, as well as by NHS Trusts across the UK, to transform the long-term management of IBD.
Ampersand Health is a social purpose company, founded by doctors and patients to improve the health and happiness of people with long-term inflammatory conditions. The company is pioneering the development of behavioral, and data-science-based digital therapies for people with immune-mediated diseases like Crohn’s, Colitis, Arthritis, and Psoriasis.
Ampersand Health is recognized in the Digital Health Global 100 and has won the HSJ Award, the NHS Ideas Lab, the NHS Hackfest, and competitive grants from government and industry. The company was selected for PWC Scale Health and the NHS’s DigitalHealth. London accelerator.
For more information: https://ampersandhealth.co.uk/
Calpro AS is internationally known for providing innovative solutions for home monitoring of IBD patients. Their home monitoring solutions enable people who suffer from IBD to take an active part in the treatment of their disease by performing CalproSmart™ self-tests at home and using the CalproSmart™ E-health App to scan and report the results to pre-determined healthcare professionals for follow up.
Calpro AS is our Norwegian-based biotech company dedicated to the research and development of Calprotectin-based diagnostic tests. Calpro AS was founded in 1993 by the inventors of the technology behind the ELISA kits for the determination of calprotectin in stools and other biological materials. Focusing on one specific biomarker, the company has a knowledge base unlike any other. The Oslo-based company has a strong position in Europe and the USA.
For more information, explore our Calprotectin Solutions